Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 3, 2011, Pages 510-516

  Manchanayake, Jayani ^a   Chitturi, Shivakumar ^a,b   Nolan, Christopher ^a,b   Farrell, Geoffrey C ^a,b  

^a Canberra Hospital   (Australia)

^b CANBERRA HOSPITAL   (Australia)

Author keywords

Cirrhosis; Diabetes complications; Fatty liver; Insulin resistance; Postprandial hyperinsulinemia; Steatohepatitis

Indexed keywords

INSULIN;

ADULT; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; PRIORITY JOURNAL;

EID: 79951634910     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06528.x     Document Type: Article

References (26)

1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112.
2. Adams LA, Lymp JF, St Sauver J etal. The natural history of non-alcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.
3. Chitturi S, Farrell GC. Fatty liver now, diabetes and heart attack later? The liver as a barometer of metabolic health. J. Gastroenterol. Hepatol. 2007; 22: 1086-91.
4. Targher G, Bertolini L, Padovani R etal. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with nonalcoholic fatty liver disease. Diabet. Med. 2006; 23: 403-9.
5. Chitturi SC, Abeygunasekera S, Farrell GC etal. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-79.
6. Marchesini G, Bugianesi E, Forlani G etal. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
7. Petersen KF, Dufour S, Hariri A etal. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N. Engl. J. Med. 2010; 362: 1082-9.
8. Angulo P, Hui JM, Marchesini G etal. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54.
9. Farrell GC, Chitturi S, Lau GKK etal. Guidelines for the assessment and management of nonalcoholic fatty liver disease in the Asia-Pacific region: executive summary. J. Gastroenterol. Hepatol. 2007; 22: 775-7.
10. Musso G, Gambino R, De Michieli F etal. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003; 37: 909-16.
11. Wong VW, Hui AY, Tsang SW etal. Prevalence of undiagnosed diabetes and postchallenge hyperglycemia in Chinese patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2006; 24: 1215-22.
12. Wong VW, Wong GL, Chim AM etal. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am. J. Gastroenterol. 2008; 103: 1682-8.
13. Matthews DR, Hosker JP, Rudenski AS etal. Homeostasis model assessment: insulin resistance and cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-19.
14. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-62.
15. World Health Organization/International Diabetes Federation. Report of WHO/IDF Consultation. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia. Geneva: WHO Press, 2006; 1-46.
16. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-25.
17. Aroda VR, Ratner R. Approach to the patient with prediabetes. J. Clin. Endocrinol. Metab. 2008; 93: 3259-65.
18. Lindström J, Ilanne-Parikka P, Peltonen M etal. Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368: 1673-9.
19. Balkau B. The DECODE study. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Diabetes Metab. 2000; 26: 282-6.
20. Starley B, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-32.
21. Sargin M, Uygur-Bayramicli O, Sargin H, Orbay E, Yayla A. Association of nonalcoholic fatty liver disease with insulin resistance: is OGTT indicated in nonalcoholic fatty liver disease? J. Clin. Gastroenterol. 2003; 37: 399-402.
22. Su CC, Wang K, Hsia TL, Chen CS, Tung TH. Association of nonalcoholic fatty liver disease with abnormal aminotransferase and postprandial hyperglycemia. J. Clin. Gastroenterol. 2006; 40: 551-4.
23. Executive summary: standards of medical care in diabetes-2010. Diabetes Care 2010; 33 (Suppl 1): S4-10.
24. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-70.
25. Saadeh S, Younossi ZM, Remer EM etal. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.
26. Yun JW, Cho YK, Park JH etal. Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease. Liver Int. 2009; 29: 525-9.